| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Min Zhang, Ting Yang, Ying-Ying Xu, Bao-Zhong Li, Wei Shen, Wen-Qing Hu, Cai-Wen Yan and Liang Zong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Wu Jieping Medical Foundation |
320.6750.2020-11-5 |
| Health Commission of Shanxi Province |
2020130 |
| Resource and Social Security of Shanxi Province |
20220056 |
|
| Corresponding Author |
Liang Zong, PhD, Doctor, Doctor, Department of Central Laboratory, Changzhi People’s Hospital, The Affiliated Hospital of Changzhi Medical College, No. 502 Changxing Middle Road, Luzhou District, Changzhi 046000, Shanxi Province, China. 250537471@qq.com |
| Key Words |
Programmed cell death protein-1 inhibitor; Chemotherapy; Oesophageal squamous cell carcinoma; Gastric/gastroesophageal junction adenocarcinoma; Overall survival; Progression-free survival; Objective response rate; Adverse event |
| Core Tip |
The combination of programmed cell death protein-1 (PD-1) inhibitor and chemotherapy is approved as a standard first- or second-line treatment in patients with advanced oesophageal or gastric cancer. However, it is unclear whether this combination is superior to chemotherapy alone. We assessed the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, or oesophageal carcinoma. Our analysis showed that immunotherapy combined with chemotherapy significantly prolonged patients’ overall survival and progression-free survival relative to the chemotherapy group, both in the overall population and in the combined positive score (CPS) ≥ 1, CPS ≥ 5, and CPS ≥ 10 subgroup. |
| Publish Date |
2024-04-11 02:23 |
| Citation |
Zhang XM, Yang T, Xu YY, Li BZ, Shen W, Hu WQ, Yan CW, Zong L. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers. World J Gastrointest Oncol 2024; 16(4): 1613-1625 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i4/1613.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i4.1613 |
